NASDAQ:APLM Apollomics (APLM) Stock Price, News & Analysis $0.14 0.00 (-0.74%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.11▼$0.2352-Week Range$0.11▼$4.26Volume251,703 shsAverage Volume1.63 million shsMarket Capitalization$12.08 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Apollomics alerts: Email Address Apollomics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,381.5% Upside$2.00 Price TargetShort InterestHealthy0.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsMedical Sector408th out of 927 stocksBiotechnology Industry3rd out of 18 stocks 3.5 Analyst's Opinion Consensus RatingApollomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageApollomics has received no research coverage in the past 90 days.Read more about Apollomics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.85% of the float of Apollomics has been sold short.Short Interest Ratio / Days to CoverApollomics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apollomics has recently decreased by 79.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldApollomics does not currently pay a dividend.Dividend GrowthApollomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APLM. Previous Next 3.3 News and Social Media Coverage News SentimentApollomics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Apollomics this week, compared to 1 article on an average week.Search InterestOnly 14 people have searched for APLM on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows3 people have added Apollomics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apollomics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 19.13% of the stock of Apollomics is held by institutions.Read more about Apollomics' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioApollomics has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Apollomics Stock (NASDAQ:APLM)Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Read More APLM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLM Stock News HeadlinesSeptember 4, 2024 | globenewswire.comApollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 14, 2024 | uk.finance.yahoo.comFlutter in talks to buy Italy's Snaitech for $2.6B, Sky News reportsSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 14, 2024 | globenewswire.comApollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressAugust 13, 2024 | msn.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataAugust 13, 2024 | msn.comApollomics stock rallies 30% on Phase 2 vebreltinib dataAugust 13, 2024 | globenewswire.comApollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialAugust 9, 2024 | finance.yahoo.comApollomics to Present at the Canaccord Genuity 44th Annual Growth ConferenceSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 19, 2024 | benzinga.comWhat's Going On With Apollomics (APLM) Stock Exploding Higher?July 16, 2024 | globenewswire.comApollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementJuly 3, 2024 | globenewswire.comApollomics Announces Updated Strategic Focus and Leadership Team ChangesMay 29, 2024 | finance.yahoo.comApollomics Announces Presentation at the 2024 BIO International ConventionMay 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline PotentialMay 8, 2024 | finance.yahoo.comApollomics Announces Private Placement Financing and Addition to Board of DirectorsApril 25, 2024 | globenewswire.comApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneApril 17, 2024 | msn.comApollomics (APLM) Price Target Decreased by 58.93% to 5.87April 16, 2024 | finance.yahoo.comApollomics, Inc. (APLM) Interactive Stock Chart - Yahoo FinanceSee More Headlines Receive APLM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:APLM CUSIPN/A CIK1944885 Webwww.apollomicsinc.com Phone886-2-7713-7952FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,338.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.95 Sales & Book Value Annual Sales$1.22 million Price / Sales10.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.29Miscellaneous Outstanding Shares89,500,000Free FloatN/AMarket Cap$12.44 million OptionableNot Optionable Beta1.17 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Guo-Liang Yu Ph.D. (Age 61)Co-Founder, CEO & Executive Chairman Dr. Matthew James Plunkett Ph.D. (Age 52)Chief Financial Officer Key CompetitorsReneo PharmaceuticalsNASDAQ:RPHMDURECTNASDAQ:DRRXRallybioNASDAQ:RLYBNabriva TherapeuticsNASDAQ:NBRVQilian International Holding GroupNASDAQ:BGMView All CompetitorsInstitutional OwnershipGeorge Kaiser Family FoundationBought 645,992 shares on 8/2/2024Ownership: 0.750%View All Institutional Transactions APLM Stock Analysis - Frequently Asked Questions How have APLM shares performed this year? Apollomics' stock was trading at $0.9650 at the beginning of 2024. Since then, APLM stock has decreased by 86.0% and is now trading at $0.1350. View the best growth stocks for 2024 here. Who are Apollomics' major shareholders? Apollomics' top institutional investors include George Kaiser Family Foundation (0.75%). How do I buy shares of Apollomics? Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APLM) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.